Compare Wayfair Inc (W) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wayfair Inc vs Zimmer Biomet Holdings Inc — how do they compare? Wayfair Inc trades at $105.75 (market cap $14.40B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wayfair Inc for 8 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| W | ZBH | |
|---|---|---|
Market Cap | $14.40B | $16.95B |
Volume | 2,102,856 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $119.05 | $103.98 |
52-Week Low | $57.40 | $79.58 |
Typical Hold Time | 8 Days | 89 Days |
Enterprise Value | $16.73B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wayfair (W) trades at $104.47, down 0.93% on the day, showing mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company reported $12.46B revenue for 2025 but posted a net loss of $313M, with negative profit margins. Recent earnings show volatility, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Analyst sentiment remains positive with a 54% buy rating and $114.13 consensus price target, while the company expands physically with new store openings.
The outlook for Wayfair hinges on improving profitability amid ongoing losses. Near-term catalysts include Q3 2026 earnings on November 4, 2026, where meeting the $0.785 EPS estimate could boost sentiment. Risks include high debt-to-asset ratio of 95.11% and competitive pressures in online retail. The stock offers 9.2% upside to the consensus target, but investors should monitor cash flow trends after 2026's negative net cash flow of $261M.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
